| Autor: |
Jourdain, Gonzague, Ngo-Giang-Huong, Nicole, Harrison, Linda, Decker, Luc, Khamduang, Woottichai, Tierney, Camlin, Salvadori, Nicolas, Cressey, Tim R., Sirirungsi, Wasna, Achalapong, Jullapong, Yuthavisuthi, Prapap, Kanjanavikai, Prateep, Na Ayudhaya, Orada P., Siriwachirachai, Thitiporn, Prommas, Sinart, Sabsanong, Prapan, Limtrakul, Aram, Varadisai, Supang, Putiyanun, Chaiwat, Suriyachai, Pornnapa, Liampongsabuddhi, Prateung, Sangsawang, Suraphan, Matanasarawut, Wanmanee, Buranabanjasatean, Sudanee, Puernngooluerm, Pichit, Bowonwatanuwong, Chureeratana, Puthanakit, Thanyawee, Klinbuayaem, Virat, Thongsawat, Satawat, Thanprasertsuk, Sombat, Siberry, George K., Watts, Diane H., Chakhtoura, Nahida, Murphy, Trudy V., Nelson, Noele P., Chung, Raymond T., Pol, Stanislas, Chotivanich, Nantasak |
| Zdroj: |
Obstetrical and Gynecological Survey; August 2018, Vol. 73 Issue: 8 p443-445, 3p |
| Abstrakt: |
(Abstracted from N Engl J Med2018;378:911–923)(Pregnant women with an elevated viral load (>200,000 IU/mL) of hepatitis B virus (HBV), or with a positive Hg e antigen (HBeAg) status, have a risk of transmitting infection to their infants, despite the infants' receiving hepatitis B immune globulin (HBIG). Antiviral agents that inhibit HBV replication, such as lamivudine, tenofovir disoproxil fumarate (TDF), and telbivudine, when administered to pregnant women with a high HBV viral load, may reduce the risk of mother-to-child transmission. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
